For: | Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. World J Gastroenterol 2013; 19(16): 2560-2568 [PMID: 23674860 DOI: 10.3748/wjg.v19.i16.2560] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i16/2560.htm |
Number | Citing Articles |
1 |
Mikko Nieminen, Mikko Salaspuro. Local Acetaldehyde—An Essential Role in Alcohol-Related Upper Gastrointestinal Tract Carcinogenesis. Cancers 2018; 10(1): 11 doi: 10.3390/cancers10010011
|
2 |
Hongli Luo, Qingze Fan, Shunlin Xiao, Kun Chen. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Services Research 2018; 18(1) doi: 10.1186/s12913-018-3358-5
|
3 |
Nele Brusselaers, Habiba (Khodir) Kamal, David Graham, Lars Engstrand. Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. BMJ Open Gastroenterology 2025; 12(1): e001719 doi: 10.1136/bmjgast-2024-001719
|
4 |
Nele Brusselaers, Karl Wahlin, Lars Engstrand, Jesper Lagergren. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017; 7(10): e017739 doi: 10.1136/bmjopen-2017-017739
|
5 |
Zuber Khan, Sidharth Mehan, Mohd. Anas Saifi, Ghanshyam Das Gupta, Acharan S. Narula, Reni Kalfin. Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the
Dementia Connection and Co-morbid Risks. Current Alzheimer Research 2023; 20(11): 739 doi: 10.2174/0115672050289946240223050737
|
6 |
Koneni V. Sashidhara, Srinivasa Rao Avula, Vaibhav Mishra, Gopal Reddy Palnati, L. Ravithej Singh, Neetu Singh, Yashpal S. Chhonker, Priyanka Swami, R.S. Bhatta, Gautam palit. Identification of quinoline-chalcone hybrids as potential antiulcer agents. European Journal of Medicinal Chemistry 2015; 89: 638 doi: 10.1016/j.ejmech.2014.10.068
|
7 |
Carmelo Scarpignato, Luigi Gatta, Angelo Zullo, Corrado Blandizzi. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine 2016; 14(1) doi: 10.1186/s12916-016-0718-z
|
8 |
Xuebiao Yao, Adam J. Smolka. Gastric Parietal Cell Physiology and Helicobacter pylori–Induced Disease. Gastroenterology 2019; 156(8): 2158 doi: 10.1053/j.gastro.2019.02.036
|
9 |
Freya Felicia D’sa, Elaine Zourra Fernandes, Srushti Vaibhav Kesarkar, Lavanya Swaminathan, Vijayanarayana Kunhikatta, Muhammed Rashid, Girish Thunga, Viji Pulikkel Chandran, Sreedharan Nair. Use of histamine‐2 receptor antagonists and risk of inflammatory bowel diseases: A systematic review and meta‐analysis of observational studies. Journal of Clinical Pharmacy and Therapeutics 2022; 47(8): 1103 doi: 10.1111/jcpt.13662
|
10 |
Takashi Kawai, Kazunori Oda, Nobuo Funao, Akira Nishimura, Yasushi Matsumoto, Yuji Mizokami, Kiyoshi Ashida, Kentaro Sugano. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018; 67(6): 1033 doi: 10.1136/gutjnl-2017-314852
|
11 |
Leon Fisher, Alexander Fisher, Paul N Smith. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). Journal of Clinical Medicine 2020; 9(10): 3253 doi: 10.3390/jcm9103253
|
12 |
Mário Dinis-Ribeiro, Diogo Libânio, Hugo Uchima, Manon C.W. Spaander, Jan Bornschein, Tamara Matysiak-Budnik, Georgios Tziatzios, João Santos-Antunes, Miguel Areia, Nicolas Chapelle, Gianluca Esposito, Gloria Fernandez-Esparrach, Lumir Kunovsky, Mónica Garrido, Ilja Tacheci, Alexander Link, Pedro Marcos, Ricardo Marcos-Pinto, Leticia Moreira, Ana Carina Pereira, Pedro Pimentel-Nunes, Marcin Romanczyk, Filipa Fontes, Cesare Hassan, Raf Bisschops, Roger Feakins, Christian Schulz, Konstantinos Triantafyllou, Fatima Carneiro, Ernst J. Kuipers. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025. Endoscopy 2025; 57(05): 504 doi: 10.1055/a-2529-5025
|
13 |
Malcolm D. Kearns, Ben Boursi, Yu-Xiao Yang. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiology 2017; 46: 80 doi: 10.1016/j.canep.2016.12.006
|
14 |
Yoshiharu Uno. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan. Cancer Medicine 2019; 8(8): 3992 doi: 10.1002/cam4.2277
|
15 |
Shuye Lin, Bonan Lin, Xiaoyue Wang, Yuanming Pan, Qing Xu, Jin-Shen He, Wanghua Gong, Rui Xing, Yuqi He, Lihua Guo, Youyong Lu, Ji Ming Wang, Jiaqiang Huang. Silencing of ATP4B of ATPase H+/K+ Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2017; 25(3): 317 doi: 10.3727/096504016X14734735156265
|
16 |
E Christina M Wennerström, Jacob Simonsen, M Constanza Camargo, Charles S Rabkin. Acid-suppressing therapies and subsite-specific risk of stomach cancer. British Journal of Cancer 2017; 116(9): 1234 doi: 10.1038/bjc.2017.84
|
17 |
Sofia Xavier, Joana Magalhães, José Cotter. Proton Pump Inhibitors: Are They a Real Threat to the Patient?. GE - Portuguese Journal of Gastroenterology 2018; 25(5): 243 doi: 10.1159/000487154
|
18 |
Karina Kofman, Michael Levin. Bioelectric pharmacology of cancer: A systematic review of ion channel drugs affecting the cancer phenotype. Progress in Biophysics and Molecular Biology 2024; 191: 25 doi: 10.1016/j.pbiomolbio.2024.07.005
|
19 |
Françoise Goirand, Isabelle Le Ray, Marc Bardou. Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2014; 10(9): 1301 doi: 10.1517/17425255.2014.939627
|
20 |
Ryuhei Maejima, Katsunori Iijima, Pertti Kaihovaara, Waku Hatta, Tomoyuki Koike, Akira Imatani, Tooru Shimosegawa, Mikko Salaspuro, Ken-ichi Mukaisho. Effects of ALDH2 Genotype, PPI Treatment and L-Cysteine on Carcinogenic Acetaldehyde in Gastric Juice and Saliva after Intragastric Alcohol Administration. PLOS ONE 2015; 10(4): e0120397 doi: 10.1371/journal.pone.0120397
|
21 |
Yuan-Yuan Lei, Wei-Jia Wang, Jin-Hong Mei, Chun-Liang Wang. Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors. Asian Pacific Journal of Cancer Prevention 2014; 15(20): 8539 doi: 10.7314/APJCP.2014.15.20.8539
|
22 |
Evan Elias, Laura E. Targownik. The Clinician’s Guide to Proton Pump Inhibitor Related Adverse Events. Drugs 2019; 79(7): 715 doi: 10.1007/s40265-019-01110-3
|
23 |
Yun Kyu Lee, Sung Soo Rho, Jae Soo Kim. Effects of Acupuncture at SP6 on Reflux Esophagitis in Rats※. The Acupuncture 2015; 32(3): 83 doi: 10.13045/acupunct.2015041
|
24 |
Nele Brusselaers, Lars Engstrand, Jesper Lagergren. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiology 2018; 53: 172 doi: 10.1016/j.canep.2018.02.004
|
25 |
Hui Huang, Wei Zhong, Xiaojiao Wang, Ying Yang, Tianmu Wu, Runyang Chen, Yanling Liu, Feng He, Jun Li. The role of gastric microecological dysbiosis in gastric carcinogenesis. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1218395
|
26 |
Yun Hong, Ziqi Ye, Zhe Gao, Yuefeng Rao. Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital. Journal of International Medical Research 2020; 48(10) doi: 10.1177/0300060520954729
|
27 |
Alla Turshudzhyan, Sonia Samuel, Angela Tawfik, Micheal Tadros. Rebuilding trust in proton pump inhibitor therapy. World Journal of Gastroenterology 2022; 28(24): 2667-2679 doi: 10.3748/wjg.v28.i24.2667
|
28 |
Yoku Hayakawa, Nilay Sethi, Antonia R. Sepulveda, Adam J. Bass, Timothy C. Wang. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap?. Nature Reviews Cancer 2016; 16(5): 305 doi: 10.1038/nrc.2016.24
|
29 |
Vito Domenico Corleto, Stefano Festa, Emilio Di Giulio, Bruno Annibale. Proton pump inhibitor therapy and potential long-term harm. Current Opinion in Endocrinology, Diabetes & Obesity 2014; 21(1): 3 doi: 10.1097/MED.0000000000000031
|
30 |
Shria Kumar, David S. Goldberg, David E. Kaplan. Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori. Digestive Diseases and Sciences 2022; 67(5): 1822 doi: 10.1007/s10620-021-06972-w
|
31 |
Jinkun Guo, Zhongyin Zhou. Proton pump inhibitors and stomach neoplasm. Oncology and Translational Medicine 2020; 6(1): 26 doi: 10.1007/s10330-019-0384-4
|
32 |
Cheol Min Shin. Acid Suppressive Drugs. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2022; 22(2): 119 doi: 10.7704/kjhugr.2022.0016
|
33 |
John Busby, Reema Karasneh, Peter Murchie, Úna McMenamin, Shahinaz M. Gadalla, M. Constanza Camargo, Lisa Iversen, Amanda J. Lee, Andrew D. Spence, Chris R. Cardwell. The role of 5α‐reductase inhibitors in gastro‐oesophageal cancer risk: A nested case‐control study. Pharmacoepidemiology and Drug Safety 2020; 29(1): 48 doi: 10.1002/pds.4909
|
34 |
Philip O. Katz, Kerry B. Dunbar, Felice H. Schnoll-Sussman, Katarina B. Greer, Rena Yadlapati, Stuart Jon Spechler. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology 2022; 117(1): 27 doi: 10.14309/ajg.0000000000001538
|
35 |
Hongli Luo, Qingze Fan, Shunlin Xiao, Kun Chen, John Green. Impact of clinical pharmacist interventions on inappropriate prophylactic acid suppressant use in hepatobiliary surgical patients undergoing elective operations. PLOS ONE 2017; 12(10): e0186302 doi: 10.1371/journal.pone.0186302
|
36 |
Mona Boudabous, Héla Gdoura, Leila Mnif, Lassad Chtourou, Amal Grati, Ali Amouri, Nabil Tahri. Esophageal Abnormalities. 2017; doi: 10.5772/intechopen.70526
|
37 |
R H Hunt, M Camilleri, S E Crowe, E M El-Omar, J G Fox, E J Kuipers, P Malfertheiner, K E L McColl, D M Pritchard, M Rugge, A Sonnenberg, K Sugano, J Tack. The stomach in health and disease. Gut 2015; 64(10): 1650 doi: 10.1136/gutjnl-2014-307595
|
38 |
Amy Lanza, Philippe Ravaud, Carolina Riveros, Agnes Dechartres, Matthew Law. Comparison of Estimates between Cohort and Case–Control Studies in Meta-Analyses of Therapeutic Interventions: A Meta-Epidemiological Study. PLOS ONE 2016; 11(5): e0154877 doi: 10.1371/journal.pone.0154877
|
39 |
Hee-Eun Hong, A-Sol Kim, Mi-Rae Kim, Hae-Jin Ko, Min Kyu Jung. Does the Use of Proton Pump Inhibitors Increase the Risk of Pancreatic Cancer? A Systematic Review and Meta-Analysis of Epidemiologic Studies. Cancers 2020; 12(8): 2220 doi: 10.3390/cancers12082220
|
40 |
Mikko Salaspuro. Key role of local acetaldehyde in upper GI tract carcinogenesis. Best Practice & Research Clinical Gastroenterology 2017; 31(5): 491 doi: 10.1016/j.bpg.2017.09.016
|
41 |
Noelia A Massari, Melisa B Nicoud, Vanina A Medina. Histamine receptors and cancer pharmacology: an update. British Journal of Pharmacology 2020; 177(3): 516 doi: 10.1111/bph.14535
|
42 |
An Tran-Duy, Bart Spaetgens, Arno W. Hoes, Niek J. de Wit, Coen D.A. Stehouwer. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016; 14(12): 1706 doi: 10.1016/j.cgh.2016.05.018
|
43 |
Akira Yokoyama, Tai Omori, Tetsuji Yokoyama. Changing trends in cancer incidence of upper aerodigestive tract and stomach in Japanese alcohol‐dependent men (1993‐2018). Cancer Medicine 2020; 9(2): 837 doi: 10.1002/cam4.2737
|
44 |
Richard H. Hunt, Mohammad Yaghoobi. The Esophageal and Gastric Microbiome in Health and Disease. Gastroenterology Clinics of North America 2017; 46(1): 121 doi: 10.1016/j.gtc.2016.09.009
|
45 |
Jeffrey K. Aronson. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC Medicine 2016; 14(1) doi: 10.1186/s12916-016-0724-1
|
46 |
David A. Johnson, Philip O. Katz, David Armstrong, Henry Cohen, Brendan C. Delaney, Colin W. Howden, Peter Katelaris, Radu I. Tutuian, Donald O. Castell. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs 2017; 77(5): 547 doi: 10.1007/s40265-017-0712-6
|
47 |
Kailin Jiang, Xiaotao Jiang, Yi Wen, Liu Liao, Feng‐bin Liu. Relationship between long‐term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. Journal of Gastroenterology and Hepatology 2019; 34(11): 1898 doi: 10.1111/jgh.14759
|
48 |
Márcia Fernanda Correia Jardim Paz, Marcus Vinícius Oliveira Barros de Alencar, Rodrigo Maciel Paulino de Lima, André Luiz Pinho Sobral, Glauto Tuquarre Melo do Nascimento, Cristiane Amaral dos Reis, Maria do Perpetuo Socorro de Sousa Coêlho, Maria Luísa Lima Barreto do Nascimento, Antonio Luiz Gomes Júnior, Kátia da Conceição Machado, Ag-Anne Pereira Melo de Menezes, Rosália Maria Torres de Lima, José Williams Gomes de Oliveira Filho, Ana Carolina Soares Dias, Antonielly Campinho dos Reis, Ana Maria Oliveira Ferreira da Mata, Sônia Alves Machado, Carlos Dimas de Carvalho Sousa, Felipe Cavalcanti Carneiro da Silva, Muhammad Torequl Islam, João Marcelo de Castro e Sousa, Ana Amélia de Carvalho Melo Cavalcante. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxidative Medicine and Cellular Longevity 2020; 2020: 1 doi: 10.1155/2020/3457890
|
49 |
Daniel Segna, Nele Brusselaers, Damian Glaus, Niklas Krupka, Benjamin Misselwitz. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211051463
|
50 |
Sadegh Fattahi, Novin Nikbakhsh, Hassan Taheri , Mohammad Ranaee, Haleh Akhavan-Niaki. RNA Sequencing of Early-Stage Gastric Adenocarcinoma Reveals Multiple Activated Pathways and Novel Long Non-Coding RNAs in Patient Tissue Samples. Reports of Biochemistry and Molecular Biology 2021; 9(4): 478 doi: 10.52547/rbmb.9.4.478
|
51 |
Rosângela Lucinda Rocha Monteiro, Maria Aparecida Marchesan Rodrigues Kobayasi, Marina Rachel de Araujo, Dafny Rocha Monteiro, Nelson Adami Andreollo. Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect?. Acta Cirúrgica Brasileira 2020; 35(9) doi: 10.1590/s0102-865020200090000004
|
52 |
Tai‐Yung Yi, Tzu‐Rong Peng, Ta‐Wei Wu, An‐Jan Wu. Association between proton pump inhibitor use and the risk of hepatobiliary cancers: A meta‐analysis. Advances in Digestive Medicine 2024; 11(3): 151 doi: 10.1002/aid2.13386
|
53 |
J. L. Schneider, F. Kolitsopoulos, D. A. Corley. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Alimentary Pharmacology & Therapeutics 2016; 43(1): 73 doi: 10.1111/apt.13450
|
54 |
Chao‐Hung Chen, Cha‐Ze Lee, Yi‐Chun Lin, Li‐Ting Kao, Herng‐Ching Lin. Negative Association of Proton Pump Inhibitors With Subsequent Development of Breast Cancer: A Nationwide Population‐Based Study. The Journal of Clinical Pharmacology 2019; 59(3): 350 doi: 10.1002/jcph.1329
|
55 |
Amit Kumar, Vandana Sahani, Shivanand Patil. A Comprehensive Review on Omeprazole: Pharmacological Effects and Its Adverse Effects. Journal for Research in Applied Sciences and Biotechnology 2025; 4(1): 38 doi: 10.55544/jrasb.4.1.4
|
56 |
Lubna Azmi, Ila Shukla, Shyam Sundar Gupta, Narayan Prasad Yadav, Padam Kant, Ch. V. Rao. In Vitro and In Vivo Study of Argyreia speciosa on Chronic Gastric Ulceration and Metabolic Studies. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences 2019; 89(3): 1039 doi: 10.1007/s40011-018-1023-8
|
57 |
Zoran Joksimović, Dušan Bastać, Snežana Pavlović. Proton pump inhibitors: Assessment of side effects and application in COVID-19 infection. Timocki medicinski glasnik 2022; 47(2-3): 96 doi: 10.5937/tmg2202096J
|
58 |
Michele Sassano, Marco Mariani, Claudio Pelucchi, Nuno Lunet, Samantha Morais, Vicente Martín, Victor Moreno, Maria Paula Curado, Emmanuel Dias-Neto, Marcis Leja, Evita Gašenko, Carlo La Vecchia, Stefania Boccia, Roberta Pastorino. Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project. Cancer Epidemiology, Biomarkers & Prevention 2023; 32(9): 1174 doi: 10.1158/1055-9965.EPI-23-0241
|
59 |
|
60 |
A. A. Sheptulin, A. A. Kirilovsky, K. S. Kirilovskaya. Side effects of proton pump inhibitors: how real are they in clinical practice?. Clinical Medicine (Russian Journal) 2024; 102(1): 57 doi: 10.30629/0023-2149-2024-102-1-57-61
|
61 |
Leonardo Henry Eusebi, Stefano Rabitti, Maria Laura Artesiani, Dania Gelli, Marco Montagnani, Rocco Maurizio Zagari, Franco Bazzoli. Proton pump inhibitors: Risks of long‐term use. Journal of Gastroenterology and Hepatology 2017; 32(7): 1295 doi: 10.1111/jgh.13737
|
62 |
Jill P. Smith, Sandeep Nadella, Nick Osborne. Gastrin and Gastric Cancer. Cellular and Molecular Gastroenterology and Hepatology 2017; 4(1): 75 doi: 10.1016/j.jcmgh.2017.03.004
|
63 |
Jeffrey K. Lee, Sophie A. Merchant, Jennifer L. Schneider, Christopher D. Jensen, Bruce H. Fireman, Charles P. Quesenberry, Douglas A. Corley. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. American Journal of Gastroenterology 2020; 115(5): 706 doi: 10.14309/ajg.0000000000000591
|
64 |
Robert Cohen Sedgh, Jungyeon Moon, Cynthia A. Jackevicius. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls. Circulation: Cardiovascular Quality and Outcomes 2021; 14(8) doi: 10.1161/CIRCOUTCOMES.120.007476
|
65 |
Yanna Ko, James Tang, Santosh Sanagapalli, Bong Sik Matthew Kim, Rupert W Leong. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opinion on Drug Safety 2016; 15(1): 53 doi: 10.1517/14740338.2016.1118050
|
66 |
Takashi Kawai, Chihiro Suzuki, Youichirou Honda, Jovelle L. Fernandez. Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study. Expert Opinion on Drug Safety 2023; 22(5): 425 doi: 10.1080/14740338.2023.2136163
|
67 |
Fiona M. Gribble, Frank Reimann, Geoffrey P. Roberts. Physiology of the Gastrointestinal Tract. 2018; : 31 doi: 10.1016/B978-0-12-809954-4.00002-5
|
68 |
Andrew Kei-Yan Ng, Pauline Yeung Ng, April Ip, Ka-Shing Cheung, Chung-Wah Siu. Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer. BMJ Open Gastroenterology 2021; 8(1): e000719 doi: 10.1136/bmjgast-2021-000719
|
69 |
Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun. Proton pump inhibitor: The dual role in gastric cancer. World Journal of Gastroenterology 2019; 25(17): 2058-2070 doi: 10.3748/wjg.v25.i17.2058
|
70 |
Aaron J. Jaworek. Laryngopharyngeal and Gastroesophageal Reflux. 2020; : 285 doi: 10.1007/978-3-030-48890-1_31
|
71 |
Sarah Amidon, Anahita Mistry, Rubina Haque. Use of Betaine HCl with Pepsin in Esophageal Cancer Patient: A Case Report. Journal of Medicinal Food 2024; 27(5): 460 doi: 10.1089/jmf.2023.0174
|
72 |
Ruijie Zeng, Yunjiu Cheng, Dongling Luo, Jinghua Wang, Jun Yang, Lei Jiang, Zewei Zhuo, Kehang Guo, Huihuan Wu, Felix W. Leung, Weihong Sha, Hao Chen. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. European Journal of Cancer 2021; 156: 190 doi: 10.1016/j.ejca.2021.07.030
|
73 |
Chang Seok Bang, Gwang Ho Baik. Acid Secretory Inhibitors and the Risk of Development of Gastric Cancer. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019; 19(1): 73 doi: 10.7704/kjhugr.2019.19.1.73
|
74 |
Rui Meng, Li‐Rong Chen, Man‐Li Zhang, Wen‐Ke Cai, Sun‐Jun Yin, Yu‐Xin Fan, Tao Zhou, Yan‐Hua Huang, Gong‐Hao He. Effectiveness and Safety of Histamine H2 Receptor Antagonists: An Umbrella Review of Meta‐Analyses. The Journal of Clinical Pharmacology 2023; 63(1): 7 doi: 10.1002/jcph.2147
|
75 |
Theresa Weltermann, Christian Schulz, Lukas Macke. Effect of frequently prescribed drugs on gastric cancer risk. Best Practice & Research Clinical Gastroenterology 2021; : 101741 doi: 10.1016/j.bpg.2021.101741
|
76 |
Peipei Liu, Úna C. McMenamin, Brian T. Johnston, Peter Murchie, Lisa Iversen, Amanda J. Lee, Pauline A. J. Vissers, Chris R. Cardwell. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. British Journal of Cancer 2020; 123(2): 307 doi: 10.1038/s41416-020-0860-4
|
77 |
Lucrezia Laterza, Franco Scaldaferri, Antonio Gasbarrini. Risk factors for gastric cancer: is it time to discard PPIs?. Gut 2019; 68(1): 176 doi: 10.1136/gutjnl-2017-315621
|
78 |
Xiao Bai, Si-Qi Ding, Xue-Ping Zhang, Ming-Hao Han, Dong-Qiu Dai. Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses. Cancers 2023; 15(2): 372 doi: 10.3390/cancers15020372
|
79 |
Haejin In, Marisa Langdon-Embry, Lauren Gordon, Clyde B. Schechter, Judith Wylie-Rosett, Philip E. Castle, M. Margaret Kemeny, Bruce D. Rapkin. Can a gastric cancer risk survey identify high-risk patients for endoscopic screening? A pilot study. Journal of Surgical Research 2018; 227: 246 doi: 10.1016/j.jss.2018.02.053
|
80 |
Mashooq Ahmad Bhat, Mohamed A. Al-Omar, Ahmed M. Naglah. Synthesis and in vivo anti-ulcer evaluation of some novel piperidine linked dihydropyrimidinone derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry 2018; 33(1): 978 doi: 10.1080/14756366.2018.1474212
|
81 |
Nasser Alkhushaym, Abdulaali R. Almutairi, Abdulhamid Althagafi, Saad B. Fallatah, Mok Oh, Jennifer R. Martin, Hani M. Babiker, Ali McBride, Ivo Abraham. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert Opinion on Drug Safety 2020; 19(3): 327 doi: 10.1080/14740338.2020.1715939
|
82 |
Man-Li Zhang, Yu-Xin Fan, Rui Meng, Wen-Ke Cai, Sun-Jun Yin, Tao Zhou, Yan-Hua Huang, Ping Wang, Fang-Fang Jiang, Mei Yang, Gong-Hao He. Proton Pump Inhibitors and Cancer Risk. American Journal of Clinical Oncology 2022; 45(11): 475 doi: 10.1097/COC.0000000000000949
|
83 |
Eun Jeong Gong, Chang Seok Bang, Dong-Kyu Kim, Jae Jun Lee, Gwang Ho Baik. Use of Proton Pump Inhibitors and the Risk for the Development of Gastric Cancers: A Nationwide Population-Based Cohort Study Using Balanced Operational Definitions. Cancers 2022; 14(20): 5172 doi: 10.3390/cancers14205172
|
84 |
Łukasz Lassmann, Matteo Pollis, Agata Żółtowska, Daniele Manfredini. Gut Bless Your Pain—Roles of the Gut Microbiota, Sleep, and Melatonin in Chronic Orofacial Pain and Depression. Biomedicines 2022; 10(7): 1528 doi: 10.3390/biomedicines10071528
|
85 |
Hyun Jin Song, Nakyung Jeon, Patrick Squires. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2020; 76(10): 1437 doi: 10.1007/s00228-020-02927-8
|
86 |
Unnur Gudnadottir, Emma Fransson, Gustaf Ljungman, Anna Wikman, Erika Vlieghe, Lars Engstrand, Nele Brusselaers. Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study. Drug Safety 2025; 48(4): 375 doi: 10.1007/s40264-024-01500-x
|
87 |
Alexander Sheh, James G Fox.
The role of the gastrointestinal microbiome in
Helicobacter pylori
pathogenesis
. Gut Microbes 2013; 4(6): 505 doi: 10.4161/gmic.26205
|
88 |
Giovanni Bruno, Piera Zaccari, Giulia Rocco, Giulia Scalese, Cristina Panetta, Barbara Porowska, Stefano Pontone, Carola Severi. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World Journal of Gastroenterology 2019; 25(22): 2706-2719 doi: 10.3748/wjg.v25.i22.2706
|
89 |
Toshihisa Takeuchi, Takahisa Furuta, Yasuhiro Fujiwara, Mitsushige Sugimoto, Kunio Kasugai, Motoyasu Kusano, Hiroyuki Okada, Takahiro Suzuki, Tomohiro Higuchi, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Akinari Sawada, Fumio Tanaka, Satoshi Harada, Kazuhiro Ota, Yuichi Kojima, Masaki Murata, Yasuhiro Tamura, Yasushi Funaki, Osamu Kawamura, Yuki Okamoto, Kazuma Fujimoto, Kazuhide Higuchi. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Alimentary Pharmacology & Therapeutics 2020; 51(5): 534 doi: 10.1111/apt.15641
|
90 |
Thomas M. Attard, Uraizee Omar, Earl F. Glynn, Nicole Stoecklein, Shawn D. St Peter, Mike A. Thomson. Gastric cancer in the pediatric population, a multicenter cross-sectional analysis of presentation and coexisting comorbidities. Journal of Cancer Research and Clinical Oncology 2023; 149(3): 1261 doi: 10.1007/s00432-022-03972-9
|